Clinical Trial Update: Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab plus lenvatinib in advanced/metastatic neuroendocrine prostate cancer; results were posted in February 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors
• Prostate Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Prostate Cancer Metastatic, Neuroendocrine Tumors | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-12